Company:  LUCID DIAGNOSTICS INC. (LUCD)
Form Type:  3
Filing Date:  10/13/2021 
CIK:  0001799011 
Address:  ONE GRAND CENTRAL PLACE
SUITE 4600
 
City, State, Zip:  NEW YORK, New York 10165 
Telephone:  212-949-4319 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.63  
Change: 
0.04 (2.52%)  
Trade Time: 
Sep 27  
Market Cap: 
$62.87M
Trade LUCD now with 

© 2022  
Description of Business
Lucid Diagnostics, Inc. ("Lucid") is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease ("GERD"), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma ("EAC"). References in this Form 10-K to "we," "us" and "our" are to Lucid and, unless the context otherwise requires, its subsidiaries. We believe that our lead products, the EsoGuard® Esophageal DNA Test performed on samples collected with the EsoCheck® Esophageal Cell Collection Device, constitute the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent EAC deaths, through early detection of esophageal precancer in at-risk GERD patients.
Register and access this filing in:     
  FORM 3
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    REPORTING OWNERS
    SIGNATURES